Abstract Library

#747 A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in Patients with Progressive Medullary Thyroid Cancer (MTC): Preliminary Data

Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2. This may explain why the available sst2–selective analogues do not work in these patients and why pasireotide (SOM230), a novel, multi-receptor targeted somatostatin analogue with high-binding affinity for sst1, 2, 3 and sst5 could be effective.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Faggiano A, Ferolla P, Vitale G, Del Prete M, Ramundo V,

Keywords: medullary thyroid cancer, pasireotide, somatostatin receptor,

#447 SOMscan: Towards a Ga-68-labeled Pan-Somatostatin PET Imaging Probe Based on SOM230 (Pasireotide)

Introduction: The somatostatin receptor subtype sst2 is largely expressed on neuroendocrine tumors. However, current clinical studies indicate that the subtypes sst1, 3, 5 are of substantial relevance as well.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Fani M, Braun F, Mann A, Kiewer A, Kaufmann J,

Keywords: SOM230, Ga-68, PET imaging,

#266 Everolimus Reduces Cell Viability in Selected Human Medullary Thyroid Carcinoma Primary Cultures

Introduction: It has been demonstrated that everolimus, an mTOR inhibitor, has a potent anti-proliferative effect in a human Medullary Thyroid Carcinoma (MTC) cell line, TT, and in two human MTC primary cultures.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Minoia M, Filieri C, Tagliati F, Buratto M, Ambrosio M,

Keywords: medullary thyroid cancer, everolimus, mTOR, antiproliferative effects,

#131 Efficacy and safety results from a Phase II study of pasireotide (SOM230) in the treatment of patients with metastatic NETs refractory or resistant to octreotide LAR

Introduction: Pasireotide, a multi-receptor targeted somatostatin analogue, has 30-, 5- and 39-fold greater affinity for sst1,3 and sst5 receptors, respectively, and a slightly lower affinity for sst2, than octreotide. Because of this multi-receptor binding profile, pasireotide may be effective in controlling symptoms of carcinoid syndrome in patients with gastroenteropancreatic neuroendocrine tumors (NETs) who are no longer responsive to currently available somatostatin analogues.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Kvols L

Authors: Kvols L, Wiedenmann B, Öberg K, Mohideen P, O’Dorisio T,

Keywords: Pasireotide, SOM230, octreotide, carcinoid, diarrhea, flushing, efficacy ,

#19 Antitumor activity of Pasireotide (SOM230) alone and in combination with Everolimus (RAD001) in DU-145 human prostate cancer model

Introduction: Pasireotide (SOM230) is a novel multi-receptor ligand somatostatin analogue with high affinity for somatostatin receptor subtypes sst1,2,3 and sst5. Like octreotide, which binds primarily to sst2, it inhibits hypersecretion of hormones from patients with functional pituitary tumors and gastroenteropancreatic neuroendocrine (GEP/NET) tumors. In addition, tumor shrinkage has been observed with both compounds in patients with acromegaly, Cushing’s disease and GEP/NETs, but its tumor-reducing mechanism of action has so far not been revealed. In patients with breast and liver cancer, octreotide had little or no antitumor activity.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Herbert Schmid

Authors: Schmid H, Chiara L, Nuciforo P,

Keywords: Pasireotide, Everolimus, SOM230, RAD001, somatostatin, prostate, solid tumors,